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Abstract: Prader-Willi syndrome (PWS) is a rare genetic condition with multi-system involvement. The literature was reviewed to describe neuro-
development and the behavioural phenotype, endocrine and metabolic disorders and respiratory and sleep functioning. Implications for child and family
quality of life were explored. Challenging behaviours contribute to poorer well-being and quality of life for both the child and caregiver. Recent evidence
indicates healthy outcomes of weight and height can be achieved with growth hormone therapy and dietary restriction and should be the current target
for all individuals with PWS. Gaps in the literature included therapies to manage challenging behaviours, as well as understanding the effects of growth
hormone on respiratory and sleep function. New knowledge regarding the transition of children and families from schooling and paediatric health ser-
vices to employment, accommodation and adult health services is also needed. Developing a national population-based registry could address these
knowledge gaps and inform advocacy for support services that improve the well-being of individuals with PWS and their families.
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Key Points
1 Food-seeking activities, restrictive or repetitive behaviours and
difﬁculties with social communication and reciprocity in individ-
uals with Prader-Willi Syndrome have signiﬁcant consequences
for maternal and family well-being.
2 Growth hormone therapy has contributed to reduced obesity,
but the optimal initiation, dosage and continuation of the ther-
apy and its effect on respiratory and sleep regulation and func-
tion remains unclear.
3 Evidence for supportive therapies in Prader-Willi Syndrome is
poor; development of evidence-based management and advo-
cacy for affected families require a more comprehensive analy-
sis of relevant covariates inﬂuencing quality of life in a large,
population-based cohort.
Prader-Willi syndrome (PWS) is a rare disorder affecting approxi-
mately 1 in 15 000 live births1,2 and results from a lack of expres-
sion of paternal genes in the 15q11-q13 region on chromosome
15. Overall life expectancy is shortened such that 13–20% of peo-
ple with PWS have died by 35 years in previously published
cohorts.3,4 Recent improvement in survival is attributed to earlier
diagnosis and greater therapeutic intervention in delaying or
preventing the onset of obesity.5
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There are many challenges for affected children and their fami-
lies. Appetite dysregulation, most notably hyperphagia, and the
difﬁcult behaviours exhibited by individuals with PWS necessitate
high levels of supervision, environmental management and behav-
ioural interventions from caregivers each day. Ongoing vigilance
and management can lead to higher levels of distress and reduced
quality of life for caregivers of individuals with PWS compared to
caregivers of individuals with other chronic congenital conditions
or the general population.6–8 This review will describe PWS, focus-
ing on appetite dysregulation, respiratory function and sleep disor-
dered breathing and challenging behaviours, and will explore their
implications for child and family well-being and quality of life.
Methods
A review of the literature describing the health and well-being of
individuals with PWS and their families was performed. The inclu-
sion of family well-being was strongly endorsed as a component in
our study by our Western Australian PWS Consumer Reference
Group. Article titles and abstracts were searched in the following
databases: Medline, PubMed, CINAHL and Google Scholar for PWS
using variations of the following key terms: health, well-being, qual-
ity of life, life satisfaction, stress, coping, managing, meaningful,
impact, psychosocial, values, burden, family functioning, family
cohesion, support, response, strain, education, affective disorders,
anxiety, depression and psychology. The references of relevant arti-
cles were also examined for inclusion in the review. Non-English
articles were excluded.
Results
Genetic cause
PWS was initially described by Prader et al. in 1956,9 with the diag-
nostic criteria revised by consensus in 199310 and revised again in
2001 to inform clinical indications for genetic testing (Table 1).2,11
PWS results from the absence of functioning paternal genes on chro-
mosome 15 in the 15q11-q13 region.2 The roles of these genes are
not completely understood, but they are known to contribute to neu-
ral development and function,12 with their absence affecting multiple
systems across the life-span (Fig. 1). Approximately 60–70% of all
PWS cases result from de novo deletions on the paternally inherited
chromosome 15 within this region, and a further 25–30% of PWS
cases are associated with maternal uniparental disomy of chromo-
some 15.2 The remainder are associated with erroneous silencing and
disrupting of the function of the paternally inherited genes in the
q11-q13 region following defects, translocations or inversions in the
imprinting centre located on the paternal chromosome 15.2
Neurodevelopmental phenotype and challenging
behaviours
Neonates with PWS may exhibit severe hypotonia, feeding difﬁcul-
ties resulting in the need for assisted feeding and failure to thrive.9,11
Other features seen during infancy include hypogonadism, mild
craniofacial abnormalities such as a narrow bi-frontal diameter and
almond shaped eyes and global developmental delay.2 Delayed
motor development is observed in most (90–100%) children with
PWS.2,13 Developmental milestones such as sitting and walking are
usually achieved at approximately double the age of typically devel-
oping children.2,13 There are limited musculoskeletal data on
strength and ﬁtness, but some evidence indicates that physical activ-
ity programmes for primary school-aged children with PWS can
increase daily physical activity.14 From 2 or 3 years of age, height
velocity usually slows, and there can be excessive weight gain with-
out strict dietary regulation.2 Children become increasingly obsessed
with food, and the majority develop the hallmark characteristic of
hyperphagia with loss of satiety.2
Variable cognitive impairment affects most individuals with
PWS, presenting as mild-to-moderate intellectual disability and
delays in language development,2,15 particularly expressive lan-
guage.16 However, intellectual functioning is classiﬁed as border-
line normal in some individuals.2,15 Difﬁculties with social
communication and reciprocity from early childhood are com-
monly reported for individuals with PWS,17,18 with difﬁculties in
establishing social relationships also described in the literature.15–17
The behavioural proﬁle of PWS also includes restricted or
repetitive behaviours.17,18 Combined with difﬁculties in social
functioning, these behaviours are sufﬁcient for a concurrent diag-
nosis of autism spectrum disorder in approximately a quarter
(26.5%, n = 786) of individuals with PWS.18 Other problematic
behaviours include emotional lability and temper tantrums, espe-
cially in response to interruption of food-seeking and repetitive
behaviours; impediments to desired goals; changes to routines; or
being presented with conﬂicting information, particularly per-
taining to unjust deviation from social expectations. Comorbid
psychiatric disorders can be common, for example, oppositional
deﬁant disorder was diagnosed in 20% of 8- to 14-year-old
Table 1 Clinical indications for diagnostic testing of Prader-Willi
syndrome (adapted from Gunay-Aygun et al.,11 Cataletto et al.63 and
Angulo et al.12)
Age at
assessment
Clinical features prompting DNA testing
Birth to 2 years Hypotonia with poor suck
Reduced fetal movement
Cryptorchidism
2–6 years Hypotonia with a history of poor suck
Global developmental delay
Short stature and/or growth failure associated with
accelerated weight gain
Hypogenitalism/Hypogonadism
6–12 years Hypotonia
Global developmental delay
Excessive eating (hyperphagia, obsession with food)
with central obesity if uncontrolled
Short stature and/or decreased growth velocity
13 years to
adulthood
Cognitive impairment, usually mild intellectual
disability
Excessive eating (hyperphagia, obsession with food)
with central obesity if uncontrolled
Hypogonadism and/or typical behaviour problems
(including temper tantrums and obsessive–
compulsive features)
Short stature and/or decreased growth velocity
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children with PWS (n = 61).19 Obsessive compulsive behaviours
include obsessions with health-related issues and compulsions
such as skin picking and rearranging objects in the environment
for increased order.19 Mental health symptoms as indicated by
scores above the clinical threshold for abnormal behaviours using
the Developmental Behaviour Checklist have been observed in
approximately three quarters of children and adolescents with
PWS.20 Neurodevelopment and behaviour are also inﬂuenced by
mutation; a meta-analysis of 744 individuals with PWS found
that, in comparison to those with deletions, those with maternal
uniparental disomy had higher intellectual quotient scores and
greater prevalence of psychosis and bipolar disorders.21
Endocrine and metabolic phenotype
Hypothalamic pituitary axis dysfunction is implicated as the under-
lying disturbance in multiple manifestations of PWS (Fig. 1).12,22,23
Fig. 1 Characteristic clinical features of the Prader-Willi syndrome phenotype in infants and toddlers under 3 years of age and in children and adoles-
cents aged 3 years and older. CVD, cardiovascular disease; T2DM, type 2 diabetes mellitus.
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Growth hormone deﬁciency
Growth hormone (GH) deﬁciency is at least in part responsible
for the characteristic clinical features of reduced growth velocity,
muscle strength, low energy expenditure and obesity in PWS.2,24
GH therapy improves growth velocity and adult height for indi-
viduals affected by PWS and maintains lean body mass with age
regardless of GH secretory status at baseline.2,24,25 The beneﬁts of
initiating GH therapy have been demonstrated for infants as
young as 2–4 months of age and through early childhood.26 Cur-
rently, many children with PWS receive GH therapy, which
lowers the body mass index (BMI) and, on average, provides the
capacity to maintain BMI below two standard deviations above
the age- and gender-matched reference values of the British
1990 normative growth charts for the duration of therapy.25,27
Other beneﬁts appear to include improved cognition28 and
behaviour29 and improved motor strength and function.30 There
is emerging evidence of the beneﬁcial effects of continuing GH
treatment into adulthood, with sustained improvements in body
composition, and deterioration of these parameters when GH is
discontinued after the attainment of adult height.31 However, as
most adults with PWS do not meet the consensus criteria for
adult GH deﬁciency, they are not eligible for subsidised GH
replacement in many jurisdictions, including Australia. The phys-
iological effects of cessation of GH therapy at 18 years of age after
many years of continuous therapy during childhood and adoles-
cence are not yet well characterised.
Metabolic disturbances and obesity-related sequelae
From birth, children with PWS have an abnormal body composi-
tion with increased fat mass and reduced lean muscle mass.
Without strictly supervised caloric restriction and regular exer-
cise, appetite disturbances and physical difﬁculties predispose the
majority of children to child-onset obesity. The Danish National
Patient Registry database reported that individuals with PWS
(n = 155) were 10 times more likely to be obese and 9 times
more likely to be diagnosed with type 2 diabetes mellitus than
the matched general population (n = 15 500).32 The development
of obesity and impaired glucose metabolism are linked to various
aspects of hypothalamic pituitary axis dysfunction. Abnormalities
in hormones inﬂuencing appetite regulation and satiety signal-
ling, such as ghrelin or peptide YY, may contribute to the hyper-
phagia in PWS.2,23 Obesity contributes to the increased risk of
obstructive sleep apnoea, cardiovascular disease, reduced bone
mineral density and fracture and scoliosis observed in patients
with PWS.2,32,33
Hypogonadism
Hypothalamic pituitary axis dysfunction also affects sexual devel-
opment through hypogonadism, which usually manifests at birth.
Almost all males with PWS have unilateral or bilateral cryptorchi-
dism, although hypoplasia of the labia minora and clitoris in girls
is less uniformly reported.22,23 Many children will commence
puberty spontaneously but will have incomplete pubertal progres-
sion or maintenance without hormone replacement therapy. This
results in infertility for nearly all individuals with PWS, although
there have been isolated case reports of pregnancies in PWS.22,23
Untreated hypogonadism contributes to central adiposity and
reduced vertebral bone mineral density.22,34 Sex steroid hormone
replacement therapy has important beneﬁts of improving linear
growth, bone health and muscle mass and may improve the emo-
tional well-being of adolescents with PWS.34
Central hypothyroidism
Cross-sectional studies have reported hypothyroidism in 72.2%
of infants under 2 years of age,35 6–24% of children and adoles-
cents36 and at rates similar to the general population in adults
with PWS.37 Longitudinal research assessing the natural course of
thyroid levels with a standard approach is required to determine
the prevalence of central hypothyroidism across the life-span of
individuals affected by PWS and for comparison with the general
population. GH therapy may unmask central hypothyroidism in
children with PWS, and annual surveillance is recommended.38
Adrenocorticotropic hormone insufﬁciency
Diagnostic tests and criteria for deﬁning central adrenal insufﬁ-
ciency vary, resulting in a reported prevalence of central adrenal
insufﬁciency in PWS ranging from 0 to 60%, with the majority of
reports suggesting that it is closest to 10%.39 Inadequate adrenal
response to stress has been suggested as one reason for reduced
clinical symptoms observed in individuals with PWS when
unwell, and has been hypothesised as a cause of unexplained
acute deaths in childhood in PWS.40 The true prevalence of adre-
nal insufﬁciency and the subsequent potential for adrenal crisis
in individuals with PWS is currently uncertain.39
Appetite dysregulation
PWS is characterised by an age-dependent spectrum of appetite
dysregulation, ranging from neonatal feeding difﬁculties with fail-
ure to thrive in infancy to the development of hyperphagia and
subsequent obesity. By maintaining clinical records of weight
gain and eating behaviours over a 10-year period (n = 58), Miller
Table 2 General phases of altered feeding patterns and growth in
Prader-Willi syndrome (adapted from phases described by Miller
et al.41)
Phase Start of phase age
range
Description
0 In utero Maternal descriptions of reduced fetal
movement, lower birthweight and
length
1a Birth Difﬁculty feeding, poor appetite and
weight gain
1b 5–15 months
Median 9 months
Improved appetite, begins to gain
weight along an expected growth
curve
2a 18–36 months
Median 2 years
Weight crosses curves, no signiﬁcant
increase in appetite or food intake
2b 3–5 years
Median 4.5 years
Increased interest in food, greater
appetite and caloric intake of food.
Children become overweight or obese
without dietary intervention
3 Pre-school – teens
Median 8 years
Hyperphagia, loss of satiety, obesity
without dietary intervention
4 >20 years (rare) Regain capacity for satiety, hyperphagia
declines or disappears
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et al. identiﬁed seven distinct phases of appetite dysregulation as
summarised in Table 2.41 Without dietary regulation and control
over access to food, obesity is likely and usually retained over the
life-span of individuals with PWS.41
Butler et al.42 found that, despite receiving a diet restricted to
60–80% of normal caloric intake for age and activity, their cohort
of children with PWS who did not receive GH (n = 120, aged
3–18 years) had weights varying between the normative 50th
centile and above the 97th centile on normative growth charts
generated from national growth data by the Centers for Disease
Control and Prevention. They also observed that the normative
50th height centile varied between the 75th and 97th growth
centiles for their cohort with PWS. These observations suggest
that children with PWS have lower caloric requirements for
weight maintenance compared with unaffected age-matched
peers. Thus, dietary regulation remains an important aspect of
management throughout the life-span.43 However, in addition to
lower energy intake, attention to macronutrient composition and
adequate levels of ﬁbre, vitamin and micronutrients is impor-
tant.44 Children for whom diet is regulated to avoid obesity
should be monitored with respect to linear growth.
Hyperphagia may also be associated with inadequate chewing
and eating unusual foods and non-food items, contributing to a
greater risk of choking and respiratory aspiration.45,46 Poor
oromotor co-ordination and gag reﬂexes, hypotonia and difﬁcul-
ties producing an adequate cough to expel excess secretions or
airway foreign bodies could further explain these increased
risks.45–47 Recent videoﬂuoroscopy swallow studies suggest aspi-
ration is common and often silent in infants with PWS.48 Exami-
nation of family-reported mortality data between 1973 and 2015
for 312 individuals with PWS in USA found that gastrointestinal
problems (e.g. perforation), choking and accidents presumed
related to food-seeking behaviours accounted for 22% of deaths
(10, 6 and 6%, respectively).33
Respiratory and sleep phenotype
Craniofacial abnormalities (Fig. 1) and a small naso- and oro-
pharynx are common in affected individuals, resulting in a rela-
tively narrow upper airway.46 The presence of obesity can further
increase upper airway resistance and is another well-known risk
factor for obstructive sleep apnoea syndrome.45 Obstructive sleep
apnoea is found in almost 80% of children with PWS,49 and
those with moderate to severe obstructive sleep apnoea exhibit
more hypoventilation and more severe desaturation during sleep
than typically developing children with a similar severity of
obstructive sleep apnoea.50 This may partly result from decreased
respiratory reserve and increased work of breathing in PWS chil-
dren related to altered ventilatory responses to hypoxia and
hypercapnia or comorbidities of obesity and scoliosis.46 Conse-
quently, children with obstructive sleep apnoea related to PWS
may be at greater risk of developing obesity hypoventilation syn-
drome than other individuals with a similar level of obesity.
Central sleep apnoea is also frequently reported in PWS, par-
ticularly in children younger than 2 years of age.51 Contributors
to central sleep apnoea include respiratory muscle hypotonia,
abnormal arousal and ventilatory control mechanisms and may
also be a downstream effect of hypothalamic dysfunction related
to hypocretin deﬁciencies.45,46 The presence of excessive daytime
sleepiness in individuals with PWS in the context of adequate
quality and quantity of sleep, even in the absence of or sufﬁcient
treatment for sleep disordered breathing and hypothyroidism,
suggests hypersomnolence is related to hypothalamic dysfunc-
tion, particularly hypocretin (also known as orexin) deﬁciencies,
causing a narcolepsy phenotype with or without cataplexy.45,46
GH treatment can have varied impacts on sleep disordered
breathing. GH may worsen obstructive sleep apnoea syndrome
symptoms by stimulating adenotonsillar and retropharyngeal
lymphoid tissue growth, but on the other hand, symptoms could
be alleviated by the beneﬁcial effects of GH on body composi-
tion.52 Although previous observational studies could not demon-
strate a consistent increase in obstructive sleep apnoea, it is
advised to regularly screen children with PWS on GH using poly-
somnography due to the risk of progressive obstructive sleep
apnoea syndrome in some individuals with potentially severe
sequelae.53 Furthermore, studies to date indicate that GH supple-
mentation may be associated with a reduction in central sleep
apnoea, but the observational nature of these studies makes it
difﬁcult to differentiate improvements due to the natural history
of PWS from effects caused by GH.53
Well-being and quality of life
Focus in the literature on neurodevelopmental disorders is
shifting to better understand the lived experiences of affected
children and their quality of life. The phenotype of PWS is associ-
ated with a complex set of physical and psychological needs that
challenge the child’s daily living, particularly in relation to hyper-
phagia, social functioning and behavioural difﬁculties. For exam-
ple, leisure activities for 123 individuals with PWS (4–48 years)
frequently included watching television, particularly those with
compulsive behaviours, with limited physical play and activities,
particularly those with greater BMI values.54 Quality of life is a
broad descriptor of well-being, and compared with typically
developing children, physical, social and mental functioning
scores have been reported to be lower for children with PWS
(n = 9 younger than 14 years, n = 20 older than 14 years).55 Sim-
ilar differences, particularly for psychosocial functioning, have
also been observed, with children with PWS (n = 44) receiving
lower scores than children with obesity but not PWS.56
A randomised controlled trial evaluating the effects of GH for
children with PWS (n = 26, median (interquartile range) age
8 (7–11 years)) found that beneﬁts for physical functioning were
accompanied by better quality of life, which was sustained over
an 11-year follow-up period.57 There is, nevertheless, limited lit-
erature on the quality of life in PWS, with interpretation ham-
pered by small sample sizes, use of different measurement tools
and lack of multivariate models investigating the determinants of
quality of life.
Longer-term social outcomes are of interest to those managing
children with PWS who will transition to adult care with time,
but the literature in this area is particularly scant. While poorer
executive and social functioning has been associated with poorer
academic attainment,15 indicators for employment and accommo-
dation outcomes are not understood. One UK survey published
in 1990 found heterogeneous outcomes with 1 in 6 of 61 young
adults with PWS achieving employment, albeit in most cases,
this was in ‘sheltered’ employment.58 Current data across a
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population are unknown but are of critical importance for family
counselling and for the planning of health and disability supports
during and after the transition period from paediatric to adult
health services and other supports.
Family and caregiver well-being
Common challenges for caregivers of children with special needs
include child sleep disturbances and behavioural and emotional
problems, which place demands on caregiver resources and a
great strain on family relationships and functioning.59,60 Delays in
diagnosis and accessing ongoing treatments and supports leads to
substantial parental stress in many rare genetic disorders.61
A high prevalence of child sleep disturbances leads to insufﬁcient
and disrupted sleep for caregivers,8 compounding the manage-
ment of daytime challenging behaviours.62 Caregiver demands in
PWS also include intensive supervision due to the need to limit
access to food.2,63 Excessive food-seeking behaviours have been
negatively correlated with maternal life satisfaction (n = 123; r =
−0.25, P = 0.001)64 and are associated with higher levels of fam-
ily stress.65 Greater availability of food outside the home environ-
ment and difﬁculties in accessing timely respite with carers who
have an adequate understanding of PWS may also restrict social
activities.7,65 Interviews with mothers of children with PWS
(n = 8) exploring parental stress and coping identiﬁed concerns
related to meeting their own personal needs and difﬁculties co-
ordinating education, work placement and other supports from
service agencies for their child.7 Siblings of children with PWS
may also experience substantial stress, and necessary supports for
them have not been explored.65
There is a complex interplay between child and parental well-
being. Studies examining this relationship in other chronic child-
hood conditions have found that challenging child behaviours
negatively affected maternal well-being, and maternal depressive
symptoms in turn negatively impacted the future behaviour of
the child.66 Research over relatively short time frames has found
each to be predictive of the other over 10 months (n = 72)67 and
2 years (n = 175).68 Further research is required to conﬁrm cau-
sality and mediating factors within these complex relationships.
Current evidence is an insufﬁcient foundation for advocacy and
service provision for affected families.
Discussion
PWS is a genetic condition with multiple neurodevelopmental fea-
tures and comorbidities necessitating ongoing medical and behav-
ioural supervision, intensive management and extensive lifestyle
modiﬁcation by caregivers and families of affected individuals. Cur-
rent comprehensive and multidisciplinary care using GH and dietary
management can help the child with PWS achieve BMI values
within normal range, and this is a clinical goal. We have identiﬁed
gaps in the understanding of musculoskeletal functioning, physical
activity and swallowing dysfunction and uncertainty on the effects
of GH on respiratory and sleep functioning. GH was approved as a
treatment for PWS in 2011, yet guidelines regarding age of initia-
tion, dosage and continuing GH therapy beyond reaching adult
height have not been established, producing cohorts with variable
use of GH therapy.24 There is a relatively high prevalence of mental
health symptoms, including challenging behaviours, that demands
systematic evaluation and management, with implications for child
and family well-being and functioning.
Interventions
Evidence-based practice
Technological innovations
Models for support
Consumer engagement
Clinical and public health 
strategies
OUTCOMESDETERMINANTS MODIFIABLE PATHWAYS
INFANT CHILD ADOLESCENT ADULT
IMPAIRMENTS: 
Genetics, muscle tone, muscle strength 
and endurance, cognitive function, 
hypothalamic pituitary axis dysfunction, 
obstructive and/or central sleep apnoea, 
appetite dysregulation, mental health 
ACTIVITY: 
Challenging behaviours, physical
fitness, communication, self-care skills
PARTICIPATION: 
Home, school, community
PERSONAL:  
Age, motivation
ENVIRONMENT:  
Social, educational and recreational 
opportunities, supports and services
CHILD QUALITY OF LIFE: 
For example increased independence, 
increased social interaction, increased 
mental well being and behavioural 
regulation
FAMILY QUALITY OF LIFE: 
For example greater social participation, 
stronger family functioning
ECONOMIC OUTCOMES: 
For example greater child and maternal 
participation in the workforce
CHILD HEALTH: 
For example reduction in obesity,
increase in height, more physical 
activity, improved sleep 
MATERNAL HEALTH:
For example reduced stress, improved 
mood, improved sleep 
Fig. 2 Model of the determinants and modiﬁable pathways at the individual, social and socio-economic levels that inﬂuence quality-of-life outcomes for
children and families affected by Prader-Willi syndrome.
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Child and family functioning are intertwined, and the symp-
toms of PWS can threaten both the child’s and caregiver’s quality
of life. Most studies examining the quality of life for individuals
with PWS and their caregivers thus far are limited in the
generalisability of their results due to sample sizes or by limited
accounting for important covariates. For example, poor sleep,
challenging behaviours and the impacts of services to support
individuals with PWS and their families are largely omitted from
analyses. There have been no studies on school functioning or
transition from paediatric to adult health services, and data on
young adult employment and accommodation are sparse.
There have been limited Australian studies of PWS.1,3,7,25,26,62
This gap is particularly relevant for Australian families with the
rollout of the National Disability Insurance Scheme where
caregivers must provide evidence of therapeutic beneﬁt from sup-
ports and services to receive funding for their child. Emotional and
educational support from parent support groups has been suggested
to moderate the social isolation and reduced quality of life for
caregivers with individuals with other chronic conditions60 but has
not been examined in PWS. The Prader-Willi Research Foundation
and the Prader-Willi Syndrome Association in Australia are two
examples of resources utilised by caregivers for individuals with
PWS. Guidance on the implementation of comprehensive multi-
disciplinary clinics for PWS warrants investigation, including
ensuring equity of access for rural and remote families.
We propose that existing gaps in the literature can be addressed
by the development of an Australian population-based registry to
enable: (i) capture of phenotypic variability; and (ii) inclusion of a
comprehensive set of variables with relevant covariates for the eval-
uation of child and family outcomes (Fig. 2). Successful examples in
Australia include the Victorian Cerebral Palsy Registry, which
includes individuals born or living in Victoria with cerebral palsy
since 1970,69 and the Australian Rett Syndrome Database, which
ascertains individuals with Rett syndrome born since 1976,70 each
capturing a population for surveillance and comprehensive research
programmes. To this end, we have initiated the process of creating
an Australasian PWS Registry to enable a population-based analysis
of variations in phenotype, the treatments and resources available
to support the needs of children with PWS and their families and
subsequent impacts on child and caregiver quality of life.
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